Logo image
Involvement of cannabinoid receptors in gut motility and visceral perception
Journal article   Open access   Peer reviewed

Involvement of cannabinoid receptors in gut motility and visceral perception

Pamela J Hornby and Stephen M Prouty
British journal of pharmacology, v 141(8), pp 1335-1345
Apr 2004
PMID: 15100166
url
https://europepmc.org/articles/pmc1574910View
Published, Version of Record (VoR)Open Access (License Unspecified) Open
url
https://doi.org/10.1038/sj.bjp.0705783View
Published, Version of Record (VoR) Open

Abstract

Animals Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators - pharmacology Cannabinoid Receptor Modulators - therapeutic use Gastrointestinal Motility - physiology Humans Pain Threshold - drug effects Pain Threshold - physiology Receptors, Cannabinoid - physiology Visceral Afferents - drug effects Visceral Afferents - metabolism Visceral Afferents - physiology
From a historical perspective to the present day, all the evidence suggests that activation of cannabinoid receptors (CBRs) is beneficial for gut discomfort and pain, which are symptoms related to dysmotility and visceral perception. CBRs comprise G-protein coupled receptors that are predominantly in enteric and central neurones (CB1R) and immune cells (CB2R). In the last decade, evidence obtained from the use of selective agonists and inverse agonists/antagonists indicates that manipulation of CB1R can alter (1) sensory processing from the gut, (2) brain integration of brain-gut axis, (3) extrinsic control of the gut and (4) intrinsic control by the enteric nervous system. The extent to which activation of CB1R is most critical at these different levels is related to the region of the GI tract. The upper GI tract is strongly influenced by CB1R activation on central vagal pathways, whereas intestinal peristalsis can be modified by CB1R activation in the absence of extrinsic input. Actions at multiple levels make the CB1R a target for the treatment of functional bowel disorders, such as IBS. Since low-grade inflammation may act as a trigger for occurrence of IBS, CB2R modulation could be beneficial, but there is little supporting evidence for this yet. The challenge is to accomplish CBR activation while minimizing adverse effects and abuse liabilities. Potential therapeutic strategies involve increasing signaling by endocannabinoids (EC). The pathways involved in the biosynthesis, uptake and degradation of EC provide opportunities for modulation of CB1R and some recent evidence with inhibitors of EC uptake and metabolism suggest that these could be exploited for therapeutic gain.

Metrics

2 Record Views
96 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pharmacology & Pharmacy
Logo image